Blue Cross and Blue Shield of Minnesota Names New CEO
Dana Erickson, a senior vice president, is moving into the top job at the Blues plan after Craig Samitt, M.D., unexpectedly resigned earlier this year.
Dana Erickson, a senior vice president at Blue Cross and Blue Shield Minnesota, has been promoted to president and CEO of the Minnesota Blues plan.
Erickson is taking over on Nov. 1 from interim CEO Kathleen Blatz who stepped into the top job at the insurer in April 2021 after Craig Samitt, M.D., unexpectedly resigned.
Erickson, a registered nurse and registered respiratory therapist, has been a member of the Blues plan’s senior leadership team since 2019 when she was appointed senior vice president and president of the health services division. In that job, Erickson has been responsible for overall strategic planning, development, implementation and administration of racial and health equity efforts, care management, provider relations, and pharmacy and medical management.
She started at Blue Cross and Blue Shield of Minnesota in 2015 as senior director of care management. Prior to the Blues plan, she held leadership positions at Univita Health and Optum Health.
"Dana is an accomplished and impressive leader who knows the healthcare industry very well, both within Minnesota and across the nation," said Michael Robinson, chair of the Board of Trustees of Blue Cross and Blue Shield of Minnesota, in a prepared statement.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More
